The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy.

Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...

CSL Behring Germany today announced that the first haemophilia B patient in Germany was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Hemophilia Treatment Center at ...

The biotech has received written agreement from the agency through the START pilot program on key aspects of its trial design for evaluating NGN-401.

“We now have emerging data to at least evaluate the efficacy of gene therapy in patients with a risk of or history of stroke,” Sharma said. “Until now, we only had one option that had a long-term ...